Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Agios Pharmaceuticals (AGIO) Gains from Sales and Divestitures (2016)

Agios Pharmaceuticals (AGIO) has disclosed Gains from Sales and Divestitures for 4 consecutive years, with $7500.0 as the latest value for Q2 2016.

  • For the quarter ending Q2 2016, Gains from Sales and Divestitures changed N/A year-over-year to $7500.0, compared with a TTM value of $7500.0 through Jun 2016, changed N/A, and an annual FY2015 reading of $8522.0, changed N/A over the prior year.
  • Gains from Sales and Divestitures was $7500.0 for Q2 2016 at Agios Pharmaceuticals, down from $8522.0 in the prior quarter.
  • Across five years, Gains from Sales and Divestitures topped out at $183713.0 in Q4 2012 and bottomed at $7500.0 in Q2 2016.
  • Average Gains from Sales and Divestitures over 4 years is $71325.8, with a median of $52367.5 recorded in 2013.